title: A New Type of Liquid Silymarin Proliposome Containing Bile Salts: Its Preparation and Improved Hepatoprotective Effects.
abstract: Silymarin, a known extract, is used in the treatment of liver diseases with various origins, but its current administration form cannot target the liver because of its poor oral bioavailability. A new type of oral silymarin proliposome aimed at improving silymarin's poor bioavailability and hepatoprotective effects, is introduced in this work. Silymarin-loaded liquid proliposome were prepared using a simple dissolving process. The morphology, particle size, zeta potential, and entrapment efficiency of the silymarin liposomes were analysed. The everted gut sac transport model was used to measure the intestinal transport of liposomes. The liposomal hepatoprotective activity was evaluated in three types of experimental hepatitis animal models. After staining with haematoxylin and eosin, the livers were microscopically examined to analyse any pathological changes. The prepared silymarin proliposome formed silymarin liposomes with a multilayer liposome structure and improved intestinal transport. In an injured liver, the silymarin liposomes produced a stronger hepatoprotective effect through a significant decrease in both the aminotransferase and MDA levels and a significant increase in the SOD and GSH-PX levels compared to orally administered silymarin tablets. This effect was also confirmed histopathologically. In a word, incorporation of silymarin into a liposomal carrier system increased intestinal absorption and showed better hepatoprotective effects compared to silymarin tablets.
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Pharmaceutical Care, PLA General Hospital, Beijing, China.
authors.forename: Tingting
authors.initials: T
authors.lastname: Xie
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Zhanying
authors.initials: Z
authors.lastname: Chang
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Xiangyun
authors.initials: X
authors.lastname: Xie
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Yaohong
authors.initials: Y
authors.lastname: Kou
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Hongxia
authors.initials: H
authors.lastname: Xu
authors.affiliation: Department of pharmaceutics, College of Pharmacy, Xinjiang Medical University, Urumqi, China.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Gao
mesh_terms: D000818:Animals; D001647:Bile Acids and Salts / Q000737:chemistry; D015415:Biomarkers; D001706:Biopsy; D004195:Disease Models, Animal; D006505:Hepatitis / Q000188:drug therapy / Q000378:metabolism; D006520:Hepatitis, Animal; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D008081:Liposomes; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D051379:Mice; D010084:Oxidation-Reduction / Q000187:drug effects; D010316:Particle Size; D020011:Protective Agents / Q000008:administration & dosage* / Q000737:chemistry; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D012838:Silymarin / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D001647:Bile Acids and Salts; D015415:Biomarkers; D008081:Liposomes; D020011:Protective Agents; D017382:Reactive Oxygen Species; D012838:Silymarin